Paper41363115
Methylation-based signature to distinguish indolent and aggressive prostate cancer.
Liao M and 4 others. Biol Open, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Methylation-based signature to distinguish indolent and aggressive prostate cancer. Papers, record 41363115. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41363115
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| DNA Methylation | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| Male | |
| Prognosis | |
| Epigenesis, Genetic | |
| Gene Expression Regulation, Neoplastic | |
| Neoplasm Grading | |
| Disease Progression | |
| Machine Learning | |
| Computational Biology |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| W81XWH-18-2-0019 | PCRP Prostate Cancer Biorepository Network | PubMed | ||
| Washington University in St Louis School of Medicine | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40063046 | Prostate Cancer: A Review. | JAMA | 2025 | https://conductscience.org/library/papers/40063046 | PubMed |
| 2 | 33079976 | Gleason Score Evolution and the Effect on Prostate Cancer Outcomes. | Am J Clin Pathol | 2021 | https://conductscience.org/library/papers/33079976 | PubMed |
| 3 | 25972926 | De novo identification of differentially methylated regions in the human genome. | Epigenetics Chromatin | 2015 | https://conductscience.org/library/papers/25972926 | PubMed |
| 4 | 37409096 | DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia. | Prostate Int | 2023 | https://conductscience.org/library/papers/37409096 | PubMed |
| 5 | 37953337 | Ensembl 2024. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/37953337 | PubMed |
| 6 | 5948714 | Classification of prostatic carcinomas. | Cancer Chemother Rep | 1966 | https://conductscience.org/library/papers/5948714 | PubMed |
| 7 | 22212080 | Staging of prostate cancer. | Histopathology | 2012 | https://conductscience.org/library/papers/22212080 | PubMed |
| 8 | 39055653 | Role of actin-binding proteins in prostate cancer. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39055653 | PubMed |
| 9 | 35437583 | Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis. | Cancer Epidemiol Biomarkers Prev | 2022 | https://conductscience.org/library/papers/35437583 | PubMed |
| 10 | 11942960 | Prognostic value of the Gleason score in prostate cancer. | BJU Int | 2002 | https://conductscience.org/library/papers/11942960 | PubMed |
| 11 | 34140313 | Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. | Genome Res | 2021 | https://conductscience.org/library/papers/34140313 | PubMed |
| 12 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 13 | 23299921 | APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. | Eur J Hum Genet | 2013 | https://conductscience.org/library/papers/23299921 | PubMed |
| 14 | 37995683 | Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. | Cancer Cell | 2023 | https://conductscience.org/library/papers/37995683 | PubMed |
| 15 | 35719272 | Biomarkers for prostate cancer detection and risk stratification. | Ther Adv Urol | 2022 | https://conductscience.org/library/papers/35719272 | PubMed |
| 16 | 39410867 | Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/39410867 | PubMed |
| 17 | 39254403 | Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects. | Asian J Androl | 2024 | https://conductscience.org/library/papers/39254403 | PubMed |
| 18 | 20808728 | Regularization Paths for Generalized Linear Models via Coordinate Descent. | J Stat Softw | 2010 | https://conductscience.org/library/papers/20808728 | PubMed |
| 19 | 31640781 | Random forest-based modelling to detect biomarkers for prostate cancer progression. | Clin Epigenetics | 2019 | https://conductscience.org/library/papers/31640781 | PubMed |
| 20 | 30729033 | Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers. | NPJ Genom Med | 2019 | https://conductscience.org/library/papers/30729033 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41363115
GET https://conductscience.org/api/papers/v1/41363115/references?page=2